Nuvalent Executive to Sell 129K Shares in Planned Transaction

Rhea-AI Filing Summary

Nuvalent officer Alexandra Balcom filed Form 144 indicating intent to sell 129,480 shares of Class A common stock with an aggregate market value of $10,358,400 through J.P. Morgan Securities. The planned sale represents approximately 0.2% of the company's 66.37 million outstanding shares.

The securities to be sold were acquired through two transactions:

• 122,396 shares via stock option exercise on June 27, 2025
• 7,084 shares from RSU vesting on January 6, 2025

The sale is being executed under a Rule 10b5-1 trading plan adopted on December 12, 2024. Some transactions will involve cashless option exercises within 3 months of filing. Notably, Balcom has not sold any company securities in the past 3 months. The filing includes standard attestation that the seller has no knowledge of material adverse non-public information.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001862147
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Nuvalent, Inc.
SEC File Number	001-40671
Address of Issuer	One Broadway, 14th floor Cambridge MASSACHUSETTS 02142
Phone	8573577000
Name of Person for Whose Account the Securities are To Be Sold	Alexandra Balcom
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A commom	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	129480	10358400	66373511	06/27/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	06/27/2025	Stock Option Exercise	Issuer			122396	06/27/2025	Cash
Class A Common	01/06/2025	RSU	Issuer			7084	01/06/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Some of the sales under this filing are from Cashless Option Exercises that will occur within 3 months from the date of this filing.
Date of Notice	06/27/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/12/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Alexandra Balcom
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of NUVL stock is Alexandra Balcom planning to sell?

According to the Form 144 filing, Alexandra Balcom, an officer at Nuvalent (NUVL), plans to sell 129,480 shares of Class A common stock through J.P. Morgan Securities LLC.

What is the total market value of NUVL shares being sold in this Form 144?

The aggregate market value of the shares to be sold is $10,358,400, as disclosed in the Form 144 filing dated June 28, 2025.

How did Alexandra Balcom acquire the NUVL shares being sold?

The shares were acquired through two methods: 122,396 shares from a Stock Option Exercise on 06/27/2025 and 7,084 shares from RSU (Restricted Stock Units) on 01/06/2025.

When does Alexandra Balcom plan to execute the NUVL stock sale?

The approximate date of sale is listed as 06/27/2025, and the filing notes that some sales will be from Cashless Option Exercises occurring within 3 months from the filing date.

Is this NUVL stock sale part of a pre-planned trading arrangement?

Yes, the filing indicates that this sale is part of a Rule 10b5-1 trading plan that was adopted on 12/12/2024.

What percentage of NUVL's outstanding shares does this planned sale represent?

The planned sale of 129,480 shares represents approximately 0.2% of Nuvalent's total outstanding shares, which are listed as 66,373,511 shares in the filing.